DOCSLIB.ORG

A Framework for Selection of Blood-Based Biomarkers for Geroscience-Guided Clinical Trials: Report from the TAME Biomarkers Workgroup

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Framework for Selection of Blood-Based Biomarkers for Geroscience-Guided Clinical Trials: Report from the TAME Biomarkers Workgroup GeroScience https://doi.org/10.1007/s11357-018-0042-y REVIEW ARTICLE A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup Jamie N. Justice & Luigi Ferrucci & Anne B. Newman & Vanita R. Aroda & Judy L. Bahnson & Jasmin Divers & Mark A. Espeland & Santica Marcovina & Michael N. Pollak & Stephen B. Kritchevsky & Nir Barzilai & George A. Kuchel Received: 2 August 2018 /Accepted: 15 August 2018 # American Aging Association 2018 Abstract Recent advances indicate that biological ag- sufficient clinical events have accumulated to test the ing is a potentially modifiable driver of late-life function study hypothesis. Since there is no standard set of bio- and chronic disease and have led to the development of markers of aging for clinical trials, an expert panel was geroscience-guided therapeutic trials such as TAME convened and comprehensive literature reviews con- (Targeting Aging with MEtformin). TAME is a pro- ducted to identify 258 initial candidate biomarkers of posed randomized clinical trial using metformin to af- aging and age-related disease. Next selection criteria fect molecular aging pathways to slow the incidence of were derived and applied to refine this set emphasizing: age-related multi-morbidity and functional decline. In (1) measurement reliability and feasibility; (2) relevance trials focusing on clinical end-points (e.g., disease diag- to aging; (3) robust and consistent ability to predict all- nosis or death), biomarkers help show that the interven- cause mortality, clinical and functional outcomes; and tion is affecting the underlying aging biology before (4) responsiveness to intervention. Application of these Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11357-018-0042-y) contains supplementary material, which is available to authorized users. J. N. Justice (*) : S. B. Kritchevsky J. L. Bahnson : J. Divers : M. A. Espeland Internal Medicine Section on Gerontology and Geriatrics, and the Department of Biostatistical Sciences, Wake Forest School of Sticht Center for Healthy Aging and Alzheimer’s Prevention, Wake Medicine, Winston-Salem, NC 27157, USA Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC 27157, USA S. Marcovina e-mail: [email protected] Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA 98109, USA L. Ferrucci National Institute on Aging, National Institutes of Health, M. N. Pollak Baltimore, MD 21224, USA Department of Oncology, Jewish General Hospital, McGill University, Montreal, Quebec H3T1E2, Canada A. B. Newman Department of Epidemiology, Graduate School of Public Health, N. Barzilai University of Pittsburgh, Pittsburgh, PA 15260, USA Department of Medicine, Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA V. R. Aroda Department of Medicine, Division of Diabetes, Endocrinology, and G. A. Kuchel Hypertension Brigham and Women’s Hospital, Harvard Medical UConn Center on Aging, University of Connecticut School of School, Boston, MA 02115, USA Medicine, Farmington, CT 06030, USA GeroScience selection criteria to the current literature resulted in a Hypothetically, a biomarker of aging should re- short list of blood-based biomarkers proposed for flect the underlying biology, and a change in bio- TAME: IL-6, TNFα-receptor I or II, CRP, GDF15, marker levels should have parallel changes that occur insulin, IGF1, cystatin C, NT-proBNP, and hemoglobin in the susceptibility to disease and loss of function. A1c. The present report provides a conceptual frame- Thus, interventions targeting aging should result in work for the selection of blood-based biomarkers for use changes in biomarkers that will eventually delay the in geroscience-guided clinical trials. This work also incidence, accumulation, clinical evolution, and revealed the scarcity of well-vetted biomarkers for hu- functional consequences of chronic age-related dis- man studies that reflect underlying biologic aging hall- eases. One of the critical roles played by biomarkers marks, and the need to leverage proposed trials for could be that of surrogate endpoints reflective of risk future biomarker discovery and validation. and progression of several major diseases. In support of this role, the US Food and Drug Administration (FDA) and the Institute of Medicine highlighted the Keywords Biomarkers . Aging . Metformin . importance of biomarkers as surrogate measures in Randomized controlled trial . Epidemiology. Mortality. drug development and trials involving chronic dis- Inflammation eases such as cancer and heart disease; however, few existing biomarkers have sufficient clinical evidence of association with the rate of development of aging Introduction phenotypes and multi-morbidity ((IOM) 2010;Bio- markers Definitions Working 2001). The FDA cur- The geroscience hypothesis holds that a specific set rently does not consider aging an indication for drug of shared biological mechanisms of aging increases development or labeling, which may also impede the the susceptibility of aged individuals to several emergence of knowledge supporting discovery and chronic diseases and loss of function and that thera- validation of geroscience-relevant biomarkers. As a pies developed to target such shared Bdrivers^ have result, there are at this time no approved or common- the potential to delay the onset and progression of ly accepted biomarkers of aging for clinical trials, nor multiple chronic diseases and functional decline. The is there a consensus set of validated biomarkers of the inter-related cellular biologic processes that drive the biologic pillars or hallmarks of aging that would be biology of aging are known as Bpillars^ or applicable to clinical research. This poses a major Bhallmarks^ of aging, and accumulating evidence translational gap that must be bridged in order to from mammalian animal models supports the pre- facilitate scientific progress. mise that geroscience-guided interventions targeting The purpose of this report is to outline a conceptual these processes can extend healthspan and lifespan framework and evidence-based approach to the prioriti- (Barzilai et al. 2016; Burch et al. 2014; Espeland zation and selection of a panel of blood biomarkers for et al. 2017; Kennedy et al. 2014; Longo et al. 2015; use in randomized controlled clinical trials of a Sierra 2016a). A new generation of clinical trials is geroscience therapy. A multi-disciplinary Biomarkers being designed to test the geroscience hypothesis in Workgroup convened for a planning workshop and humans (Justice et al. 2016;Newmanetal.2016b; met weekly by phone over an 8-month period. The Sierra 2016b). One example is the proposed multi- Biomarkers Workgroup defined biomarker criteria, center clinical trial, Targeting Aging with MEtformin prioritized selection parameters, and provided guid- (TAME), which will evaluate whether metformin, a ance for resource development and inclusion of commonly used diabetes drug that also targets the biol- discovery-based platforms. The development of the ogy of aging, can (1) prevent or delay the incidence of TAME trial served as an opportunity to apply the multiple age-related chronic diseases, (2) help maintain selection criteria to putative blood-based biomarkers function, and (3) influence biological markers of aging identified through an exhaustive literature review. in older persons (Barzilai et al. 2016). To accomplish The result is an evidence-based short list of proposed this latter aim, a strategy to select the most appropriate biomarkers for the TAME trial, and a framework that biomarkers of aging to be included in geroscience- could be applied to next-generation clinical trials guided clinical trials is needed. targeting aging. GeroScience Conceptual framework The criteria above were developed for research stud- ies in humans. Foundational efforts to identify and cat- Biomarker definitions According to consensus defini- egorize the cellular and molecular Bhallmarks^ of aging tions by Baker and Sprott (Baker III and Sprott 1988; introduced a host of potential biomarkers for mammali- Sprott 1988, 2010), and the American Federation for an aging based on evidence in mouse models and some Aging Research (AFAR), biomarkers of aging are simpler organisms such as Caenorhabditis elegans and measures of a biological parameter that, either Drosophila melanogaster. Clinical translation of these alone or as a multivariate composite, monitor a biomarkers can be problematic, with barriers such as biological process underlying aging rather than ef- access to tissues, environmental or genetic control, and fects of a specific disease; predict the rate of aging use of resource and assays that are not feasible in clinical and mortality better than chronological age; can be research. However, reports often mix evidence from safely tested across repeat measures in the same animal models and humans indiscriminately, and aside organism; and work in humans and in laboratory from a few thoughtful reviews and studies, relative- animals such as mice. The Biomarkers Workgroup ly, little work has emerged on measures of the adapted these definitions to develop selection biologic Bhallmarks^ of aging specifically for hu- criteria tailored to the context of geroscience- man research (Burkle et al. 2015;Khanetal.2017; guided randomized clinical trials: Rochon et al. 2011). Accordingly, the present framework presented focuses solely
Load more

Recommended publications
  • Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span
    Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span Sofiya Milman1,2 and Nir Barzilai1,2,3 1Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, New York, New York 10461 2Institute for Aging Research, Albert Einstein College of Medicine, New York, New York 10461 3Department of Genetics, Albert Einstein College of Medicine, Bronx, New York 10461 Correspondence: [email protected] Humans age at different rates and families with exceptional survival provide the opportunity to understand why some people age slower than others. Unique features exhibited by cen- tenarians include a family history of longevity, compression of morbidity with resultant extension of health span, and biomarkers such as low-circulating insulin-like growth factor 1 (IGF-1) and elevated high-density lipoprotein (HDL) cholesterol levels. Given the rarity of the centenarian phenotype, it has not been surprising that the use of discovery methods that relied on common population single nucleotide polymorphisms (SNPs) to unlock the genetic determinants of exceptional longevity have not yielded significant results. Conversely, gene sequencing has resulted in discoveries of functional gene variants that support several of the centenarian phenotypes. These discoveries have led to the strategic developments of drugs that may delay aging and prolong health span. THE RATIONALE FOR STUDYING HUMAN diseases have in common. To put these statistics EXCEPTIONAL LONGEVITY in perspective, elevated low-density lipoprotein (LDL) cholesterol level, which is one of the best www.perspectivesinmedicine.org he Unites States government annually pub- known and aggressively treated risk factors for Tlishes a report on the rate of death from in- heart disease, the most common cause of death dividual diseases, stratified by age groups.
    [Show full text]
  • Metformin Regulates Metabolic and Nonmetabolic Pathways in Skeletal Muscle and Subcutaneous Adipose Tissues of Older Adults
    Accepted: 11 December 2017 DOI: 10.1111/acel.12723 SHORT TAKE Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults Ameya S Kulkarni1,2,3* | Erika F Brutsaert1,2* | Valentin Anghel1 | Kehao Zhang1 | Noah Bloomgarden1 | Michael Pollak4 | Jessica C Mar2,5,6 | Meredith Hawkins1,2,7 | Jill P Crandall1,2,7 | Nir Barzilai1,2,7 1Division of Endocrinology, Department of Medicine, Albert Einstein College of Summary Medicine, Bronx, NY, USA Administration of metformin increases healthspan and lifespan in model systems, 2Institute for Aging Research, Albert and evidence from clinical trials and observational studies suggests that metformin Einstein College of Medicine, Bronx, NY, USA delays a variety of age-related morbidities. Although metformin has been shown to 3Institute for Clinical and Translational modulate multiple biological pathways at the cellular level, these pleiotropic effects Research, Albert Einstein College of Medicine, Bronx, NY, USA of metformin on the biology of human aging have not been studied. We studied 4Department of Oncology, McGill ~70-year-old participants (n = 14) in a randomized, double-blind, placebo-controlled, University, Montreal, QC, Canada crossover trial in which they were treated with 6 weeks each of metformin and pla- 5Department of Systems and Computational Biology, Albert Einstein cebo. Following each treatment period, skeletal muscle and subcutaneous adipose College of Medicine, Bronx, NY, USA tissue biopsies were obtained, and a mixed-meal challenge test was performed. As 6 Australian Institute for Bioengineering and expected, metformin therapy lowered 2-hour glucose, insulin AUC, and insulin Nanotechnology, University of Queensland, Brisbane, QLD, Australia secretion compared to placebo.
    [Show full text]
  • Ageing: Science, Technology and Healthy Living
    HOUSE OF LORDS Science and Technology Select Committee 1st Report of Session 2019–21 Ageing: Science, Technology and Healthy Living Ordered to be printed 1 December 2020 and published 15 January 2021 Published by the Authority of the House of Lords HL Paper 183 Science and Technology Committee The Science and Technology Select Committee is appointed by the House of Lords in each session “to consider science and technology”. Membership The Members of the Science and Technology Committee are: Baroness Blackwood of North Oxford Lord Patel (Chairman) Lord Borwick Viscount Ridley Lord Browne of Ladyton Baroness Rock Baroness Hilton of Eggardon Baroness Sheehan Lord Hollick Baroness Walmsley Lord Kakkar Lord Winston (co-opted) Lord Mair Baroness Young of Old Scone Baroness Mannigham-Buller Declaration of interests See Appendix 1. A full list of Members’ interests can be found in the Register of Lords’ Interests: http://www.parliament.uk/mps-lords-and-offices/standards-and-interests/register-of-lords- interests Publications All publications of the Committee are available at: http://www.parliament.uk/hlscience Parliament Live Live coverage of debates and public sessions of the Committee’s meetings are available at: http://www.parliamentlive.tv Further information Further information about the House of Lords and its Committees, including guidance to witnesses, details of current inquiries and forthcoming meetings is available at: http://www.parliament.uk/business/lords Committee staff The staff who worked on this inquiry were Dr Simon Cran-McGreehin (Clerk), Dr Amy Creese (Policy Analyst) and Cerise Burnett-Stuart (Committee Assistant). Contact details All correspondence should be addressed to the Science and Technology Committee, Committee Office, House of Lords, London SW1A 0PW.
    [Show full text]
  • Nir Barzilai, MD
    Nir Barzilai, M.D. - Curriculum Vitae Albert Einstein College of Medicine Belfer Building, Suite 701 1300 Morris Park Avenue Bronx, NY 10461 CURRENT HOSPITAL AND ACADEMIC APPOINTMENTS Chair: The Ira and Ingeborg Rennert Chair for Aging Research Director: Institute for Aging Research, Albert Einstein College of Medicine; Bronx, NY Director: Animal Physiology Core of the NIH funded Diabetes Research and Training Center Professor: Department of Medicine and Molecular Genetics, Albert Einstein College of Medicine The Ingeborg and Ira Leon Rennert Chair of Aging Research Clinical : Co-Director: Diabetes Clinic; Montefiore Medical Center; Bronx NY, Attending Physician Medicine and Endocrinology: Jacobi Hospital; Weiler Hospital; Bronx, NY. Albert Einstein College of Medicine PREVIOUS APPOINTMENTS 1993-94 Instructor of Medicine: Division of Endocrinology; Diabetes Research Center; Albert Einstein College of Medicine; Bronx, NY 1994-99 Assistant Professor of Medicine: Divisions of Endocrinology and Geriatrics; Diabetes Research Center; Albert Einstein College of Medicine 2002- 04 Associate Professor of Medicine and Molecular Genetics: Albert Einstein College of Medicine CERTIFICATION AND LICENSURE 1989 Board Certification Internal Medicine; Israel 1995 Board Certification Internal Medicine; US 1996 Board eligible Endocrinology and Metabolism; US 1 EDUCATION 1978-85 Technion, Faculty of Medicine (7 year accelerated MD program) 1979 Summer student: Neoplastic Biochemistry, Department of Pharmacology; Baylor College of Medicine; Houson, TX 1980 Clerkship: Baragwanath Hospital, Department of Pediatrics; Soweto, South Africa. 1980 Clerkship: Charles Johnson Memorial Hospital; Medical Clinics and Community Health projects (the creation of a nutritional village); Kwazulu Homeland, South Africa 1981 Summer student: Glucose Transport Systems, National Institutes of Health (NIDDK); Bethesda, MD 1982-85 Doctoral research project: Glucose and Insulin Metabolism in Endocrinopathies: Hyperthyroidism, Cushing’s, Obesity, Acanthosis Nigricans.
    [Show full text]
  • The Goal of Geroscience Is Life Extension
    www.oncotarget.com Oncotarget, 2021, Vol. 12, (No. 3), pp: 131-144 Research Perspective The goal of geroscience is life extension Mikhail V. Blagosklonny1 1Roswell Park Cancer Institute, Buffalo, NY 14263, USA Correspondence to: Mikhail V. Blagosklonny, email: [email protected], [email protected] Keywords: aging; longevity; rapamycin; mTOR; metformin Received: December 23, 2020 Accepted: January 13, 2021 Published: February 02, 2021 Copyright: © 2021 Blagosklonny. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Although numerous drugs seemingly extend healthspan in mice, only a few extend lifespan in mice and only one does it consistently. Some of them, alone or in combination, can be used in humans, without further clinical trials. INTRODUCTION healthspan without lifespan (e.g., resveratrol), and discuss how to proceed with clinical application of lifespan- “Although we do not know everything about extending drugs. aging, we now know enough to start its pharmacologic suppression using clinically approved drugs.” Published Failure of anti-oxidants in 2010, these opening words of the paper entitled “Increasing healthy lifespan by suppressing aging in our The goal of longevity research is life extension. lifetime: preliminary proposal” are still relevant today Instead, most studies are focused on life-shortening. Many [1]. The proposal was based on hyperfunction theory things can shorten lifespan without causing normal aging. that aging is a continuation of development, driven in For example, car accidents shorten lifespan, but they do part by growth-promoting pathways, such as mTOR [2].
    [Show full text]